The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions

Recently, the morbidity and mortality of pancreatic cancer have been increasing year by year. Because of its deep anatomical location and because most presented patients often suffer from abdominal pain or jaundice, it is difficult to diagnose pancreatic cancer at an early stage, leading to late clinical stage and poor prognosis. integrated positron emission tomography/magnetic resonance imaging (PET/MRI) fusion imaging not only has the characteristics of high resolution and multi-parameter imaging of MRI, but also combines the high sensitivity and the semi-quantitative characteristics of PET. In addition, the continuous development of novel MRI imaging and PET imaging biomarkers provide a unique and precise research direction for future pancreatic cancer research. This review summarizes the value of PET/MRI in the diagnosis, staging, efficacy monitoring, and prognosis evaluation of pancreatic cancer, and prognosis for developing emerging imaging agents and artificial intelligence radiomics in pancreatic cancer.

[1]  V. Bettinardi,et al.  68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Nan Li,et al.  Pretherapeutic Assessment of Pancreatic Cancer: Comparison of FDG PET/CT Plus Delayed PET/MR and Contrast-Enhanced CT/MR , 2022, Frontiers in Oncology.

[3]  E. Moros,et al.  Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer , 2021, Radiation oncology.

[4]  J. McConathy,et al.  Applications of PET/MRI in Abdominopelvic Oncology. , 2021, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  E. O’Reilly,et al.  Pancreatic Cancer: A Review. , 2021, JAMA.

[6]  A. Iagaru,et al.  Clinical Applications of PET/MR Imaging. , 2021, Radiologic clinics of North America.

[7]  Yu-Ting Chang,et al.  Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome , 2021, Diagnostics.

[8]  R. Braren,et al.  [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma , 2021, EJNMMI Research.

[9]  L. Evangelista,et al.  The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review , 2021, Annals of Nuclear Medicine.

[10]  V. Bettinardi,et al.  Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms , 2021, Diagnostics.

[11]  X. Lan,et al.  Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Jeffrey W. Clark,et al.  Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study , 2021, Molecular Imaging and Biology.

[13]  P. Yadav,et al.  Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy , 2021, Diagnostics.

[14]  M. Huellner.  PET/MR in Head and Neck Cancer - An Update. , 2021, Seminars in nuclear medicine.

[15]  B. Kemp,et al.  Borderline Resectable and Locally Advanced Pancreas Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Neoadjuvant Therapy Pathologic Response and Prediction of Survival. , 2020, AJR. American journal of roentgenology.

[16]  John O. Prior,et al.  Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma , 2020, European Radiology.

[17]  A. Wetter,et al.  Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI , 2020, Nuclear Medicine and Molecular Imaging.

[18]  A. Skulimowski,et al.  Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature , 2020, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  Xiaozhu Lin,et al.  Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience , 2020, Frontiers in Oncology.

[20]  Naveen M. Kulkarni,et al.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals , 2019, Abdominal Radiology.

[21]  Peter Schirmacher,et al.  The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.

[22]  P. Woodard,et al.  PET/MR Imaging in Cardiovascular Imaging. , 2019, PET clinics.

[23]  A. Dabrowski,et al.  Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club , 2019, Przeglad gastroenterologiczny.

[24]  R. Turkington,et al.  Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes , 2018, World journal of gastroenterology.

[25]  A. Guimaraes,et al.  PET/MR Imaging of the Pancreas. , 2018, Magnetic resonance imaging clinics of North America.

[26]  E. Collisson,et al.  Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. , 2018, AJR. American journal of roentgenology.

[27]  B. Erickson,et al.  PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study12 , 2018, Translational oncology.

[28]  A. Schmid,et al.  PET/MRI Hybrid Systems. , 2018, Seminars in nuclear medicine.

[29]  Zibo Li,et al.  Development of [18F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. , 2018, Molecular pharmaceutics.

[30]  A. Stoita,et al.  Challenges in diagnosis of pancreatic cancer , 2018, World journal of gastroenterology.

[31]  Yu-Ting Chang,et al.  Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Ashley Gillman,et al.  PET motion correction in context of integrated PET/MR: Current techniques, limitations, and future projections , 2017, Medical physics.

[33]  F. Song,et al.  Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy , 2017, BMJ Open.

[34]  Elliot K Fishman,et al.  Diagnosis and Detection of Pancreatic Cancer , 2017, Cancer journal.

[35]  David M. Wilson,et al.  The Role of PET/MR Imaging in Precision Medicine. , 2017, PET clinics.

[36]  Bin Zhou,et al.  Early detection of pancreatic cancer: Where are we now and where are we going? , 2017, International journal of cancer.

[37]  Zibo Li,et al.  Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma , 2017, Amino Acids.

[38]  U. Metser,et al.  Comparison of 18F-FDG-PET/CT and 18F-FDG-PET/MR imaging in oncology: a systematic review , 2017, Annals of Nuclear Medicine.

[39]  Zhengyu Jin,et al.  Intraductal Papillary Mucinous Neoplasm of the Pancreas With High Malignant Potential on FDG PET/MRI. , 2016, Clinical nuclear medicine.

[40]  I. Ilic,et al.  Epidemiology of pancreatic cancer , 2016, World journal of gastroenterology.

[41]  A. Burls.  Critical appraisal , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[42]  James S Babb,et al.  Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer. , 2016, Radiology.

[43]  C. H. Nielsen,et al.  PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site–Inhibited Factor VII , 2016, The Journal of Nuclear Medicine.

[44]  Yu-Ting Chang,et al.   PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  P. Jha,et al.  PET/CT for Pancreatic Malignancy: Potential and Pitfalls , 2015, The Journal of Nuclear Medicine Technology.

[46]  B R Rosen,et al.  Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients , 2015, British Journal of Cancer.

[47]  Kelley Tipton,et al.  Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma , 2014 .

[48]  W. Weber.  PET/MR Imaging: A Critical Appraisal , 2014, The Journal of Nuclear Medicine.

[49]  K. Gurusamy,et al.  Resection versus other treatments for locally advanced pancreatic cancer. , 2014, The Cochrane database of systematic reviews.

[50]  H. Quick.  Integrated PET/MR , 2014, Journal of magnetic resonance imaging : JMRI.

[51]  Hideyuki Wakamatsu,et al.  The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT , 2013, Annals of Nuclear Medicine.

[52]  Michela Matteoli,et al.  Biocompatible nanocomposite for PET/MRI hybrid imaging , 2012, International journal of nanomedicine.

[53]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[54]  E. Leen,et al.  Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[55]  Masatoshi Hori,et al.  18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT , 2011, International Journal of Clinical Oncology.

[56]  W. Weber.  Clinical PET/MR. , 2020, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[57]  Vespasiani-Gentilucci,et al.  Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes , 2018 .

[58]  Marco Salvatore,et al.  Hybrid PET/MRI Methodology. , 2018, International review of neurobiology.

[59]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[60]  M. Hashizume,et al.  Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent. , 2018, Biomaterials.

[61]  Eun Sun Lee,et al.  Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study. , 2017, Radiology.

[62]  E. Ornstein,et al.  The Potential and the Pitfalls , 2008 .

[63]  Asphalt Pavement Mixes,et al.  DEVELOPMENT OF A , 2011 .

[64]  Teresa Foo,et al.  : SYSTEMATIC LITERATURE REVIEW , 2004 .

[65]  Chantal Wouters,et al.  An exploratory study , 2003 .

[66]  Robert C. Wolpert,et al.  A Review of the , 1985 .